{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:12:56Z","timestamp":1719015176978},"posted":{"date-parts":[[2024,4,1]]},"group-title":"In Review","reference-count":51,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,3,25]]},"abstract":"<title>Abstract<\/title>\n        <p>Cerebral amyloid angiopathy is characterized by a weakening of the small and medium sized cerebral arteries, as their smooth muscle cells are progressively replaced with acellular amyloid \u03b2, increasing vessel fragility and vulnerability to microhemorrhage. In this context, an aberrant overactivation of the complement system would further aggravate this process. The surface protein CD59 protects most cells from complement-induced cytotoxicity, but expression levels can fluctuate due to disease and vary between cell types. The degree to which CD59 protects human cerebral vascular smooth muscle (HCSM) cells from complement-induced cytotoxicity has not yet been determined. To address this shortcoming, we selectively blocked the activity of HCSM-expressed CD59 with an antibody and challenged the cells with complement, then measured cellular viability. Unblocked HCSM cells proved resistant to all tested concentrations of complement, and this resistance decreased progressively with increasing concentrations of anti-CD59 antibody. Complete CD59 blockage, however, did not result in total loss of cellular viability, suggesting that additional factors may have some protective functions. Taken together, this implies that CD59 plays a predominant role in HCSM cellular protection against complement-induced cytotoxicity. Over-expression of CD59 could be an effective means of protecting these cells from excessive complement system activity, with consequent reduction in the incidence of microhemorrhage. The precise extent to which cellular repair mechanisms and other complement repair proteins contribute to this resistance has yet to be fully elucidated.<\/p>","DOI":"10.21203\/rs.3.rs-4165045\/v1","type":"posted-content","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T18:15:00Z","timestamp":1711995300000},"source":"Crossref","is-referenced-by-count":0,"title":["CD59 Protects Primary Human Cerebrovascular Smooth Muscle Cells from Cytolytic Membrane Attack Complex"],"prefix":"10.21203","author":[{"given":"Carson","family":"Whinnery","sequence":"first","affiliation":[{"name":"Loma Linda University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Nie","sequence":"additional","affiliation":[{"name":"Loma Linda University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo S.","family":"Boskovic","sequence":"additional","affiliation":[{"name":"Loma Linda University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Soriano","sequence":"additional","affiliation":[{"name":"Loma Linda University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolff M.","family":"Kirsch","sequence":"additional","affiliation":[{"name":"Loma Linda University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1161\/01.str.18.2.311","article-title":"Cerebral amyloid angiopathy. A critical review","volume":"18","author":"Vinters HV","year":"1987","unstructured":"Vinters HV (1987) Cerebral amyloid angiopathy. A critical review. Stroke 18(2):311\u2013324. https:\/\/doi.org\/10.1161\/01.str.18.2.311","journal-title":"Stroke"},{"issue":"2","key":"ref2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1750-3639.2009.00322.x","article-title":"Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain pathology (Zurich, Switzerland)","volume":"20","author":"Soontornniyomkij V","year":"2010","unstructured":"Soontornniyomkij V et al (2010) Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain pathology (Zurich, Switzerland). 20(2):459\u2013467. https:\/\/doi.org\/10.1111\/j.1750-3639.2009.00322.x"},{"issue":"4","key":"ref3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/bpa.12005","article-title":"A shift in microglial \u03b2-amyloid binding in Alzheimer's disease is associated with cerebral amyloid angiopathy","volume":"23","author":"Zabel M","year":"2013","unstructured":"Zabel M et al (2013) A shift in microglial \u03b2-amyloid binding in Alzheimer's disease is associated with cerebral amyloid angiopathy. Brain Pathol 23(4):390\u2013401. https:\/\/doi.org\/10.1111\/bpa.12005","journal-title":"Brain Pathol"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/0976-3147.80107","article-title":"Sporadic cerebral amyloid angiopathy: An important cause of cerebral hemorrhage in the elderly","volume":"2","author":"Bano S","year":"2011","unstructured":"Bano S et al (2011) Sporadic cerebral amyloid angiopathy: An important cause of cerebral hemorrhage in the elderly. J Neurosci Rural Pract 2(1):87\u201391. https:\/\/doi.org\/10.4103\/0976-3147.80107","journal-title":"J Neurosci Rural Pract"},{"issue":"1","key":"ref5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/ana.25123","article-title":"Person-specific contribution of neuropathologies to cognitive loss in old age","volume":"83","author":"Boyle PA","year":"2018","unstructured":"Boyle PA et al (2018) Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol 83(1):74\u201383. https:\/\/doi.org\/10.1002\/ana.25123","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3233\/JAD-2009-1073","article-title":"Serial Susceptibility Weighted MRI Measures Brain Iron and Microbleeds in Dementia","volume":"17","author":"Kirsch W","year":"2009","unstructured":"Kirsch W et al (2009) Serial Susceptibility Weighted MRI Measures Brain Iron and Microbleeds in Dementia. J Alzheimers Dis 17:599\u2013609. https:\/\/doi.org\/10.3233\/JAD-2009-1073","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"ref7","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/jnen\/62.12.1287","article-title":"Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis\/lipohyalinosis with cognitive decline","volume":"62","author":"Thal DR","year":"2003","unstructured":"Thal DR et al (2003) Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis\/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 62(12):1287\u20131301. https:\/\/doi.org\/10.1093\/jnen\/62.12.1287","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10571-016-0334-7","article-title":"The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline","volume":"36","author":"Corriveau RA","year":"2016","unstructured":"Corriveau RA et al (2016) The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline. Cell Mol Neurobiol 36(2):281\u2013288. https:\/\/doi.org\/10.1007\/s10571-016-0334-7","journal-title":"Cell Mol Neurobiol"},{"issue":"4","key":"ref9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11883-012-0254-z","article-title":"The pathophysiology and clinical presentation of cerebral amyloid angiopathy","volume":"14","author":"Auriel E","year":"2012","unstructured":"Auriel E, Greenberg SM (2012) The pathophysiology and clinical presentation of cerebral amyloid angiopathy. Curr Atheroscler Rep 14(4):343\u2013350. https:\/\/doi.org\/10.1007\/s11883-012-0254-z","journal-title":"Curr Atheroscler Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21061992","author":"Tanaka M","year":"2020","unstructured":"Tanaka M et al (2020) Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease. International journal of molecular sciences, 21(6): p. 1992 https:\/\/doi.org\/10.3390\/ijms21061992"},{"issue":"2\u20133","key":"ref11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s0161-5890(01)00055-4","article-title":"Complement and apoptosis","volume":"38","author":"Fishelson Z","year":"2001","unstructured":"Fishelson Z, Attali G, Mevorach D (2001) Complement and apoptosis. Mol Immunol 38(2\u20133):207\u2013219. https:\/\/doi.org\/10.1016\/s0161-5890(01)00055-4","journal-title":"Mol Immunol"},{"issue":"5","key":"ref12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1084\/jem.110.5.699","article-title":"Effect of antibody and complement on permeability control in ascites tumor cells and erythrocytes","volume":"110","author":"Green H","year":"1959","unstructured":"Green H, Barrow P, Goldberg B (1959) Effect of antibody and complement on permeability control in ascites tumor cells and erythrocytes. J Exp Med 110(5):699\u2013713. https:\/\/doi.org\/10.1084\/jem.110.5.699","journal-title":"J Exp Med"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj2640001","article-title":"Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects","volume":"264","author":"Morgan BP","year":"1989","unstructured":"Morgan BP (1989) Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 264(1):1\u201314. https:\/\/doi.org\/10.1042\/bj2640001","journal-title":"Biochem J"},{"issue":"1","key":"ref14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger JR","year":"2010","unstructured":"Dunkelberger JR, Song W-C (2010) Complement and its role in innate and adaptive immune responses. Cell Res 20(1):34\u201350. https:\/\/doi.org\/10.1038\/cr.2009.139","journal-title":"Cell Res"},{"issue":"2","key":"ref15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.molimm.2015.01.020","article-title":"Contribution of the complement Membrane Attack Complex to the bactericidal activity of human serum","volume":"65","author":"Berends ETM","year":"2015","unstructured":"Berends ETM et al (2015) Contribution of the complement Membrane Attack Complex to the bactericidal activity of human serum. Mol Immunol 65(2):328\u2013335. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.molimm.2015.01.020","journal-title":"Mol Immunol"},{"issue":"20","key":"ref16","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1523\/JNEUROSCI.20-20-07505.2000","article-title":"Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease","volume":"20","author":"Yang LB","year":"2000","unstructured":"Yang LB et al (2000) Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J neuroscience: official J Soc Neurosci 20(20):7505\u20137509. https:\/\/doi.org\/10.1523\/JNEUROSCI.20-20-07505.2000","journal-title":"J neuroscience: official J Soc Neurosci"},{"issue":"4","key":"ref17","first-page":"542","article-title":"The expression of CD59 in normal human nervous tissue","volume":"82","author":"Vedeler C","year":"1994","unstructured":"Vedeler C et al (1994) The expression of CD59 in normal human nervous tissue. Immunology 82(4):542\u2013547","journal-title":"Immunology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bbi.2017.04.023","article-title":"Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes","volume":"65","author":"Wang Z","year":"2017","unstructured":"Wang Z et al (2017) Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes. Brain Behav Immun 65:173\u2013182. https:\/\/doi.org\/10.1016\/j.bbi.2017.04.023","journal-title":"Brain Behav Immun"},{"issue":"1","key":"ref19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/(sici)1097-0185(199609)246:1<78::Aid-ar9>3.0.Co;2-b","article-title":"Human complement regulator expression by the normal female reproductive tract","volume":"246","author":"Oglesby TJ","year":"1996","unstructured":"Oglesby TJ, Longwith JE, Huettner PC (1996) Human complement regulator expression by the normal female reproductive tract. Anat Rec 246(1):78\u201386. https:\/\/doi.org\/10.1002\/(sici)1097-0185(199609)246:1<78::Aid-ar9>3.0.Co;2-b","journal-title":"Anat Rec"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.02008","author":"Michielsen LA","year":"2018","unstructured":"Michielsen LA et al (2018) Reduced Expression of Membrane Complement Regulatory Protein CD59 on Leukocytes following Lung Transplantation. Frontiers in Immunology, 8(2008) https:\/\/doi.org\/10.3389\/fimmu.2017.02008"},{"issue":"2\u20133","key":"ref21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-3083.2007.01959.x","article-title":"CD59 Efficiently Protects Human NT2-N Neurons Against Complement-mediated Damage","volume":"66","author":"Pedersen ED","year":"2007","unstructured":"Pedersen ED et al (2007) CD59 Efficiently Protects Human NT2-N Neurons Against Complement-mediated Damage. Scand J Immunol 66(2\u20133):345\u2013351. https:\/\/doi.org\/https:\/\/doi.org\/10.1111\/j.1365-3083.2007.01959.x","journal-title":"Scand J Immunol"},{"issue":"1","key":"ref22","first-page":"1","article-title":"Human protectin (CD59), an 18,000\u201320,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers","volume":"71","author":"Meri S","year":"1990","unstructured":"Meri S et al (1990) Human protectin (CD59), an 18,000\u201320,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71(1):1\u20139","journal-title":"Immunology"},{"issue":"20","key":"ref23","doi-asserted-by":"crossref","first-page":"13418","DOI":"10.1016\/S0021-9258(18)98856-3","article-title":"Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement","volume":"266","author":"Zhao J","year":"1991","unstructured":"Zhao J et al (1991) Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J Biol Chem 266(20):13418\u201313422","journal-title":"J Biol Chem"},{"issue":"Pt 2","key":"ref24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1113\/jphysiol.2001.013381","article-title":"CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9","volume":"539","author":"Farkas I","year":"2002","unstructured":"Farkas I et al (2002) CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9. J Physiol 539(Pt 2):537\u2013545. https:\/\/doi.org\/10.1113\/jphysiol.2001.013381","journal-title":"J Physiol"},{"issue":"11","key":"ref25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas MC","year":"2020","unstructured":"Dalakas MC, Alexopoulos H, Spaeth PJ (2020) Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Reviews Neurol 16(11):601\u2013617. https:\/\/doi.org\/10.1038\/s41582-020-0400-0","journal-title":"Nat Reviews Neurol"},{"issue":"12","key":"ref26","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.ejca.2014.05.005","article-title":"The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack","volume":"50","author":"Kesselring R","year":"2014","unstructured":"Kesselring R et al (2014) The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack. Eur J Cancer 50(12):2152\u20132161. https:\/\/doi.org\/10.1016\/j.ejca.2014.05.005","journal-title":"Eur J Cancer"},{"issue":"3","key":"ref27","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/ajt.13497","article-title":"A Promoter Polymorphism in the CD59 Complement Regulatory Protein Gene in Donor Lungs Correlates With a Higher Risk for Chronic Rejection After Lung Transplantation","volume":"16","author":"Budding K","year":"2016","unstructured":"Budding K et al (2016) A Promoter Polymorphism in the CD59 Complement Regulatory Protein Gene in Donor Lungs Correlates With a Higher Risk for Chronic Rejection After Lung Transplantation. Am J Transplant 16(3):987\u2013998. https:\/\/doi.org\/10.1111\/ajt.13497","journal-title":"Am J Transplant"},{"issue":"12","key":"ref28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/ard.55.12.888","article-title":"Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane","volume":"55","author":"Konttinen YT","year":"1996","unstructured":"Konttinen YT et al (1996) Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis 55(12):888\u2013894. https:\/\/doi.org\/10.1136\/ard.55.12.888","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"ref29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","article-title":"Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors","volume":"40","author":"Fishelson Z","year":"2003","unstructured":"Fishelson Z et al (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40(2):109\u2013123. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/S0161-5890(03)00112-3","journal-title":"Mol Immunol"},{"issue":"6","key":"ref30","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1212\/NXG.0000000000000280","article-title":"Molecular pathogenesis of human CD59 deficiency","volume":"4","author":"Karbian N","year":"2018","unstructured":"Karbian N et al (2018) Molecular pathogenesis of human CD59 deficiency. Neurol Genet 4(6):e280. https:\/\/doi.org\/10.1212\/NXG.0000000000000280","journal-title":"Neurol Genet"},{"issue":"2","key":"ref31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0006-8993(99)01514-0","article-title":"Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease","volume":"833","author":"Yasojima K","year":"1999","unstructured":"Yasojima K, McGeer EG, McGeer PL (1999) Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Brain Res 833(2):297\u2013301. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/S0006-8993(99)01514-0","journal-title":"Brain Res"},{"issue":"9","key":"ref32","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1167\/iovs.08-2025","article-title":"Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE","volume":"49","author":"Ramo K","year":"2008","unstructured":"Ramo K, Cashman SM, Kumar-Singh R (2008) Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE. Invest Ophthalmol Vis Sci 49(9):4126\u20134136. https:\/\/doi.org\/10.1167\/iovs.08-2025","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"ref33","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ana.24770","article-title":"Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation","volume":"80","author":"Mevorach D","year":"2016","unstructured":"Mevorach D et al (2016) Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation. Ann Neurol 80(5):708\u2013717. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/ana.24770","journal-title":"Ann Neurol"},{"issue":"6","key":"ref34","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.2353\/ajpath.2010.091172","article-title":"Lack of complement inhibitors in the outer intracranial artery aneurysm wall associates with complement terminal pathway activation","volume":"177","author":"Tulamo R","year":"2010","unstructured":"Tulamo R et al (2010) Lack of complement inhibitors in the outer intracranial artery aneurysm wall associates with complement terminal pathway activation. Am J Pathol 177(6):3224\u20133232. https:\/\/doi.org\/10.2353\/ajpath.2010.091172","journal-title":"Am J Pathol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1010164","DOI":"10.3389\/fnins.2022.1010164","article-title":"Vascular smooth muscle cell dysfunction in neurodegeneration","volume":"16","author":"Hayes G","year":"2022","unstructured":"Hayes G et al (2022) Vascular smooth muscle cell dysfunction in neurodegeneration. Front Neurosci 16:1010164. https:\/\/doi.org\/10.3389\/fnins.2022.1010164","journal-title":"Front Neurosci"},{"issue":"4","key":"ref36","doi-asserted-by":"publisher","first-page":"C869","DOI":"10.1152\/ajpcell.00154.2007","article-title":"Intermediate filaments in smooth muscle","volume":"294","author":"Tang DD","year":"2008","unstructured":"Tang DD (2008) Intermediate filaments in smooth muscle. Am J Physiol Cell Physiol 294(4):C869\u2013C878. https:\/\/doi.org\/10.1152\/ajpcell.00154.2007","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"ref37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1084\/jem.146.1.22","article-title":"Austen Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins","volume":"146","author":"Fearon D","year":"1977","unstructured":"Fearon D (1977) Austen Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med 146(1):22\u201333. https:\/\/doi.org\/10.1084\/jem.146.1.22","journal-title":"J Exp Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of Serological Complement Biomarkers in Disease","volume":"9","author":"Ekdahl KN","year":"2018","unstructured":"Ekdahl KN et al (2018) Interpretation of Serological Complement Biomarkers in Disease. Front Immunol 9. https:\/\/doi.org\/10.3389\/fimmu.2018.02237","journal-title":"Front Immunol"},{"issue":"9","key":"ref39","doi-asserted-by":"publisher","first-page":"e45851","DOI":"10.1371\/journal.pone.0045851","article-title":"Effect of Serum Heat-Inactivation and Dilution on Detection of Anti-WNV Antibodies in Mice by West Nile Virus E-protein Microsphere Immunoassay","volume":"7","author":"Namekar M","year":"2012","unstructured":"Namekar M et al (2012) Effect of Serum Heat-Inactivation and Dilution on Detection of Anti-WNV Antibodies in Mice by West Nile Virus E-protein Microsphere Immunoassay. PLoS ONE 7(9):e45851. https:\/\/doi.org\/10.1371\/journal.pone.0045851","journal-title":"PLoS ONE"},{"issue":"2","key":"ref40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/0006-8993(94)01264-I","article-title":"Complement-mediated neurotoxicity is regulated by homologous restriction","volume":"671","author":"Shen Y","year":"1995","unstructured":"Shen Y, Halperin JA, Lee C-M (1995) Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res 671(2):282\u2013292. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/0006-8993(94)01264-I","journal-title":"Brain Res"},{"issue":"6","key":"ref41","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3892\/or_00000368","article-title":"Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells","volume":"21","author":"Zhao W-P","year":"2009","unstructured":"Zhao W-P et al (2009) Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep 21(6):1405\u20131411. https:\/\/doi.org\/10.3892\/or_00000368","journal-title":"Oncol Rep"},{"issue":"6","key":"ref42","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/(SICI)1097-0215(19970611)71:6<1049::AID-IJC22>3.0.CO;2-7","article-title":"Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer","volume":"71","author":"Jarvis GA","year":"1997","unstructured":"Jarvis GA et al (1997) Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 71(6):1049\u20131055. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/(SICI)1097-0215(19970611)71:6<1049::AID-IJC22>3.0.CO;2-7","journal-title":"Int J Cancer"},{"issue":"1","key":"ref43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1582-4934.2007.00213.x","article-title":"The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine","volume":"12","author":"Eyden B","year":"2008","unstructured":"Eyden B (2008) The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J Cell Mol Med 12(1):22\u201337. https:\/\/doi.org\/10.1111\/j.1582-4934.2007.00213.x","journal-title":"J Cell Mol Med"},{"issue":"3","key":"ref44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.yexcr.2005.11.004","article-title":"Multiple roles of alpha-smooth muscle actin in mechanotransduction","volume":"312","author":"Wang J","year":"2006","unstructured":"Wang J, Zohar R, McCulloch CA (2006) Multiple roles of alpha-smooth muscle actin in mechanotransduction. Exp Cell Res 312(3):205\u2013214. https:\/\/doi.org\/10.1016\/j.yexcr.2005.11.004","journal-title":"Exp Cell Res"},{"issue":"1","key":"ref45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1034\/j.1600-065X.2001.1800104.x","article-title":"Role of the C5b-9 complement complex in cell cycle and apoptosis","volume":"180","author":"Rus HG","year":"2001","unstructured":"Rus HG, Niculescu FI, Shin ML (2001) Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 180(1):49\u201355. https:\/\/doi.org\/https:\/\/doi.org\/10.1034\/j.1600-065X.2001.1800104.x","journal-title":"Immunol Rev"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4049\/jimmunol.137.1.263","article-title":"Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2\u2009+\u2009and association with cellular Ca2+","volume":"137","author":"Carney DF","year":"1986","unstructured":"Carney DF, Hammer CH, Shin ML (1986) Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2\u2009+\u2009and association with cellular Ca2+. J Immunol 137(1):263\u2013270","journal-title":"J Immunol"},{"issue":"12","key":"ref47","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1073\/pnas.80.12.3816","article-title":"Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics","volume":"80","author":"Koski CL","year":"1983","unstructured":"Koski CL et al (1983) Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci U S A 80(12):3816\u20133820. https:\/\/doi.org\/10.1073\/pnas.80.12.3816","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ref48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jaci.2004.02.003","article-title":"Clinical and laboratory evaluation of complement deficiency","volume":"113","author":"Wen L","year":"2004","unstructured":"Wen L, Atkinson JP, Giclas PC (2004) Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol 113(4):585\u2013593. https:\/\/doi.org\/10.1016\/j.jaci.2004.02.003","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"ref49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1128\/iai.05956-11","article-title":"Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein","volume":"80","author":"Giuntini S","year":"2012","unstructured":"Giuntini S, Reason DC, Granoff DM (2012) Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect Immun 80(1):187\u2013194. https:\/\/doi.org\/10.1128\/iai.05956-11","journal-title":"Infect Immun"},{"issue":"49","key":"ref50","doi-asserted-by":"publisher","first-page":"48921","DOI":"10.1074\/jbc.M302598200","article-title":"Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo","volume":"278","author":"Fraser DA","year":"2003","unstructured":"Fraser DA et al (2003) Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. J Biol Chem 278(49):48921\u201348927. https:\/\/doi.org\/10.1074\/jbc.M302598200","journal-title":"J Biol Chem"},{"issue":"11","key":"ref51","first-page":"3013","article-title":"CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma","volume":"60","author":"Chen S","year":"2000","unstructured":"Chen S et al (2000) CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res 60(11):3013\u20133018","journal-title":"Cancer Res"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4165045\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4165045\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T20:05:57Z","timestamp":1719000357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4165045\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":51,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4165045\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.3390\/brainsci14060601","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,4,1]]},"subtype":"preprint"}}